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Abstract
Alzheimer’s disease (AD) is the most common progressive neurodegenerative disease known to humankind. It is
characterized by brain atrophy, extracellular amyloid plaques, and intracellular neurofibril tangles. b-amyloid cascade is
considered the major causative player in AD. Up until now, the mechanisms underlying the process of Ab generation and
accumulation in the brain have not been well understood. Tyro3 receptor belongs to the TAM receptor subfamily of
receptor protein tyrosine kinases (RPTKs). It is specifically expressed in the neurons of the neocortex and hippocampus. In
this study, we established a cell model stably expressing APPswe mutants and producing Ab. We found that overexpression
of Tyro3 receptor in the cell model significantly decreased Ab generation and also down-regulated the expression of b-site
amyloid precursor protein cleaving enzyme (BACE1). However, the effects of Tyro3 were inhibited by its natural ligand, Gas6,
in a concentration-dependent manner. In order to confirm the role of Tyro3 in the progression of AD development, we
generated an AD transgenic mouse model accompanied by Tyro3 knockdown. We observed a significant increase in the
number of amyloid plaques in the hippocampus in the mouse model. More plaque-associated clusters of astroglia were also
detected. The present study may help researchers determine the role of Tyro3 receptor in the neuropathology of AD.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegener-
ative disease known to humankind and a major form of dementia.
It impairs basic cognitive functions, primarily memory [1,2]. The
etiology and pathogenesis of the disease are still not yet well
understood. AD is characterized by three age-dependent patho-
logical features. The deposition of amyloid plaques occurs mainly
extracellularly. These are also called senile plaques (SP), or neuritic
plaques. SPs and neurofibrillary tangles (NFTs) are caused by the
intraneuronal hyperphosphorylation of Tau protein and apoptotic
neuronal death [3,4,5]. These features are most evident in the
neocortex and hippocampus. As the main component of neuritic
plaques, the amyloid b peptides (Ab) are considered key molecules
in the pathogenesis of AD [6,7]. Ab peptides are viewed as the
culprit of this disease. They act as the main trigger for a series of
processes known as the amyloid cascade [8]. This cascade
generally culminates in apoptotic neuronal death. These amyloi-
dogenic peptides are derived from an integral membrane protein,
called amyloid precursor protein (APP), which is cleaved by the
proteases b- and c-secretase through a two-step proteolytic
process. Although APP amyloidogenic processing produces
fragments of different lengths, Ab40 and Ab42, have 40 and 42
amino acids, respectively, and they are the two most abundant of
Ab [7,9–11]. Ab42 aggregates at a much faster rate and at a lower
concentration than other fragments. Robust evidence confirming
the amyloid cascade hypothesis has been gathered from studies of
AD transgenic mice carrying human missense mutant APP and
presenilin-1 (PS1) genes, which encode mutant human APP and
PS1 proteins that can produce much more Ab, especially Ab42
[9,12]. These mouse models share some aspects of human AD,
such as amyloid plaques, neuron and synapse loss, and correlative
memory deficits.
The Tyro3 family is a subfamily of receptor tyrosine kinases
(RPTKs). It comprises Rse/Tyro3, Axl/UFO, and Mer/Eyk [13–
17]. These three receptors share a ligand-binding ectodomain,
a single membrane-spanning domain, and a cytoplasmic tyrosine
kinase domain [18,19]. The tyro3 gene is expressed during central
nervous system neurogenesis and exhibits distinct and highly
regionalized patterns of expression in the adult brain [19–21]. In
human tissues, especially, the highest concentration of expression
of tyro3 mRNA is observed in the brain. Tyro3 is expressed at high
levels in the mouse cerebral cortex and hippocampus. Moreover,
the highest levels of Tyro3 expression in the brain are associated
with neurons [14,21–23]. Two related proteins, the growth arrest
specific gene product Gas6 and protein S, have been identified as
ligands of TAM family receptors [24,25]. Gas6 functions as
a ligand for TAM receptors and can protect cortical neurons from
b-amyloid induced apoptosis [26]. It can also attenuate serum-
starvation-induced cell death in the hippocampal and gonadotro-
pin-releasing neurons [27,28]. Gas6 has also exhibited trophic
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central and peripheral nervous systems [29,30]. Recent reports
have shown that Tyro3 receptors are closely related to
immunodysfunction in the central nervous system [31–33]. The
region-specific expression of Tyro3 suggests that it may play an
important role in the development and biological functions of the
central nervous system. Tyro3/Axl/Mer triple knockout brains
have exhibited altered histology and increased rates of apoptosis
and cellular degeneration [18,19]. We have also demonstrated that
nerve growth factor (NGF) insufficiency is considered major
factors in cholinergic neuronal degeneration in the brains of
organisms with AD [34–36]. NGF induces both Tyro3 and Axl
expression in differentiating PC12 cells, and these receptors
interact with TrkA, which is a receptor specific to NGF. Activation
of Tyro3 by Gas6 protects PC12 cells from death induced by
serum starvation and NGF deprivation [37,38]. All of these
aforementioned observations suggest that Tyro3 receptor may has
a protective effect against the progression of AD. To date,
however, the functions of Tyro3 receptor in pathology of AD
remain unclear.
All of the above indicate that Tyro3 receptor may regulate the
formation of AD pathology. In the present study, we used human
APPswe transgenic models in vitro and in vivo to determine
whether Tyro3 affects Ab production and Ab deposition. We
observed that the APP processing mediated by BACE1 was
inhibited by Tyro3 overexpression in vitro, and the number of
senile plaques resulting from Ab deposition was increased by
Tyro3 gene knockdown in an AD mouse model.
Results
Effects of Tyro3 overexpression on Ab production from
HEK293 cells stably expressing APPswe mutants
To determine whether Tyro3 receptor could affect APP
processing and Ab production we first established a cell line,
HEK293 cells stably overexpressing APPswe mutants (here called
293APPswe cells). This line is characterized overexpression of
human APP695 proteins (110 KD) (Figure S1) and producing
excessive Ab, especially Ab42 by the APP processing compared
with undetectable production of wild type HEK293 cells (data not
shown). In the next step, we transfected a Tyro3-CFP chimera
transiently to the 293APPswe cells. GFP expression plasmid was
used to transfect the cells as a control. After 24 h of transfection,
Tyro3 protein overexpression in those cells was clarified using
confocal imaging and Western blot analysis (Figure 1). As shown in
Figure 1A and B, Tyro3-CFP chimera mainly expressed on the
membrane but also in cytosol, in contrast with diffused GFP
expression pattern in control cells (Figure 1A and C). Our ELISA
analysis showed that Tyro3 overexpression significantly reduced
both the production of Ab42 and Ab40 (Figure 2 A and B), as well
the ratio Ab42/Ab40 (Figure 2C). These data suggest that Tyro3
receptor overexpression is related to the generation of Ab and APP
processing.
Effects of Gas6 on decreases in Ab production induced
by Tyro3 overexpression
Tyro3 can be activated by its natural ligands. To further
determine whether the effects of Tyro3 on the production of Ab
depends on its ligand, Gas6, we subjected 293APPswe cells
transfected with GFP or Tyro3-CFP to media lacking or
containing Gas6 at final concentration of 100 ng/ml. After 24 h
of treatment, we observed that Tyro3 overexpression similarly
reduced the production of Ab40 and Ab42 in the absence of Gas6.
However, these effects were completely inhibited in the presence
of Gas6 (Figure 2A and B). To exclude the possibility that the
inhibitory effect of Gas6 at the final concentration of 100 ng/ml
was caused by a high concentration of reagents, we also used 12.5,
25, 50, and 100 ng/ml of Gas6 to treat 293APPswe cells
overexpressing Tyro3-CFP and GFP. Tyro3 overexpression was
found to significantly reduce the production of Ab, including Ab40
and Ab42, in the absence of Gas6 and in the presence of Gas6 at
final concentrations of 12.5 or 25 ng/ml. However, it had no effect
on the total Ab levels secreted by 293APPswe cells in the presence
of Gas6 at final concentrations of 50 or 100 ng/ml (Figure 2D).
The result also showed that Gas6 inhibits the decreases in Ab
production induced by Tyro3 overexpressing in a concentration-
dependent manner. This suggests that the effect of Tyro3 on Ab
production is not only independent of its ligand, Gas6, but can also
be inhibited by Gas6.
Effects of Tyro3 overexpression on BACE1 and CTFs
expression
The b-secretase, b-site amyloid precursor protein cleaving
enzyme (BACE1), is responsible for initiating Ab generation. The
BACE1 first cuts APP to generate the N terminus of Ab,
producing a membrane-bound C-terminal fragment called C99.
Then c-secretase cleaves C99 to release the mature Ab peptide.
Alternatively, APP can be cleaved by a-secretase within the Ab
domain to generate C83 and preclude Ab generation [7,9,11,39].
To determine whether the decrease in Ab production is caused by
the alleviation of APP processing induced by BACE1 down-
regulation, which could be instigated by Tyro3 overexpression in
293APPswe cells, we incubated the 293APPswe cells overexpres-
sing GFP or Tryo3-CFP in the medium in the absence or presence
of Gas6 at different concentration of 12.5, 25, 50 or 100 ng/ml.
The protein extracts were subjected to Western blot assay and we
observed that the protein level of BACE1 is significantly lower in
293APPswe cells overexpressing Tyro3 than in GFP control cells
(Figure 3A, B). As the metabolites of APP cleaved by BACE1, C99
(bCTF) also is reduced in Tyro3 overexpressing cells, while, C83
(aCTF) expression is increased by Tryo3 overexpression in
293APPswe cells, simultaneously (Figure 3C, D, E). The result
suggests that Tyro3 could not only alter BACE1 protein level but
also regulate BACE1 activity. Next, we evaluated the effects of
Gas6 on BACE1 protein expression because Gas6 had inhibited
the decrease in Ab production induced by Tyro3 overexpression.
There was no statistically significant effect of Tyro3 overexpression
was detected in the presence of Gas6 at any final concentration of
BACE1 protein expression in the 293APPswe cells compared to
control cells, although Tyro3 overexpression in the presence of
Gas6 at a final concentration of 12.5 ng/ml tended to reduce the
production of Ab (Figure 4A, B). This suggests that Tyro3
overexpression reduces Ab production at least in part through
downregulation of BACE1 protein expression in 293APPswe cells
and that the effects of Tyro3 receptor on amyloidogenic APP
processing and Ab generation are not only independent of Gas6
but can be inhibited by Gas6.
Effects of Tyro3 receptor partial knockdown on amyloid
plaque formation in the CA1 hippocampus and
subiculum of 5XFAD transgenic mouse brains
Given that Tyro3 receptor overexpression ameliorated the
generation of Ab, especially that of Ab42, in APPswe mutant cell
model, we anticipated that Tyro3 also would affect Ab accumu-
lation in the brains of APP/PS1 mutant mice. To determine
whether Tyro3 receptor could influence Ab deposition in vivo, we
generated the 5XFAD; Tyro3
2/+ transgenic mice by crossing
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2/2). Age-
matched 5XFAD transgenic mice were used as controls. As in
previous studies, we found that immunostaining with an Ab-
specific monoclonal antibody, anti-6E10, revealed the 5XFAD
mice had obvious amyloid deposition in the cerebral cortex and
hippocampus at 6 months of age (Figure 5A–C, G–I) [40]. Ab
deposition was dramatically increased in the CA1 region of the
hippocampus in 5XFAD; Tyro3
2/+ mouse brains (Figure 5D–F).
This was statistically significantly different from 5XFAD trans-
genic mice. Although the number of amyloid plaques in the cortex
of 5XFAD; Tyro3
2/+ mice did not exhibit distinguishable
differences from 5XFAD transgenic mice (Figure 5G–L, R).
Unexpectedly, the number of amyloidal plaques deposited in the
dentate gyruses (DG) displayed was slightly lower in 5XFAD;
Tyro3
2/+ transgenic mice than in 5XFAD transgenic mice, as
shown in Figure 5A–F, R. However, Ab deposition showed a much
more diffuse pattern in 5XFAD; Tyro3
2/+ transgenic brains than
in 5XFAD controls. The enlarged confocal laser scanning images
Figure 1. Tyro 3-CFP transiently overexpressing in 293APPswe cells. (A) In live 293APPswe cells, Tyro3-CFP fusion and green fluorescent
protein (GFP), phase contrast image, and merged image were observed by confocol microscopy after 24 h of transfection with CMV-Tyro3-CFP and
CMV-GFP, respectively. The merged portrait consists of transfected cells, and the bar scale is 100 mm. Transfection efficiency of CMV-Tyro3-CFP in
293APPswe is equal to that of CMV-GFP in these cells. (B) Enlarged image from 293APPswe cells overexpressing Tyro3-CFP. (C) Enlarged image from
293APPswe cells overexpressing GFP. (D) Western blot for Tyro3 of protein extracts from GFP transfected 293APPswe cells and Tyro3-CFP transfected
293APPswe cells. The protein level of Tyro3 in 293APPswe cells transfected with CMV-Tyro3-CFP was found to be higher than in controls transfected
with CMV-GFP. GAPDH was used as a loading control. (E) Statistical analysis showed a significant increase in the level of Tyro3 in the Tyro3-CFP
overexpressing cells (***P,0.001).
doi:10.1371/journal.pone.0039035.g001
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were similar to those previously described and specific to Ab
[3,4,6]. This was confirmed by the staining wild-type mouse
brains, which showed almost no immuno-positive plaques for anti-
6E10 antibody staining (data not shown). It is noteworthy that the
amyloid deposits in subiculum of 5XFAD; Tyro3
2/+ transgenic
brain were vastly more numerous than those observed in the
5XFAD transgenic brain (Figure 5P, Q, S). Moreover, as shown in
Figures 5P and 5Q, enlarged images of Ab-immunoreactive
plaques demonstrated that amyloid deposits in 5XFAD; Tyro3
2/+
transgenic mice were typically smaller but had greater plaque seed
density than that of 5XFAD transgenic mice, possibly because of
the highly elevated Ab42 levels in 5XFAD; Tyro3
2/+ transgenic
mice.
We also used Congo red dye to stain plaques and detected
astrogliosis, simultaneously using astrocyte specific marker GFAP
immunostaining. We found that 5XFAD mice had relatively
diffuse distribution of GFAP-immunoreactive (GFAP-ir) astroglial
cells and congophilic plaque-associated clusters of astroglia
(Figure 6A–C). Partial Tyro3 knockdown (Figure 6D–F) caused
an increase in the area occupied by GFAP-ir cells and optical
density of GFAP stainning around congophilic plaques (Figure 6G,
H). To determine whether partial Tyro3 knockdown affects the
microglial activation in the 5XFAD mouse brain, we next
examined the microglial reactivity in mouse brains using Iba1
(ionized calcium binding adaptor molecule 1) that is specifically
expressed in macrophages/microglia antibody. However, no
significant difference in the immunoreactivity of Iba1 positive
cells was found between 5XFAD transgenic mice and 5XFAD;
Tyro3
2/+ mice (Figure 7).
Discussion
Although increasing numbers of genetic and pathological
studies implicate alterations in APP processing as being central
to AD mechanisms, the causative factors influencing Ab gener-
ation and deposition remain unclear. APP has a single membrane-
spanning domain, with a long extracellular N-terminal and short
intracellular C-terminal region. Ab is derived from APP, which is
cleaved by b-secretase (also called BACE, b-site APP cleaving
enzyme) and c-secretase, sequentially. Normally, the generation of
Ab peptides is at equilibrium and less pronounced than the
products cleaved by a-secretase from APP [7,9,39]. However, Ab
production was found to be increased significantly by the APP
mutations associated with early-onset familial AD [12,41]. The
present study demonstrated that overexpression of APP with the
Swedish mutant promotes the production of Abs, especially Ab42,
in HEK293 cells, as reported previously [42,43]. In this way, the
cell model overexpressing the Swedish mutant APP should be
a better tool to research the procedure of amyloidogenic APP
processing and Ab generation associated with AD pathogenesis. In
the first step of our study, we explored whether Tyro3 receptor
could affect APP processing and Ab production (because the
Tyro3 receptor is preferentially expressed in neurons of the
cerebral cortex and hippocampus) and which parts of the brain are
involved in AD progression [13,14,21,23]. We found that Tyro3-
CFP is expressed mainly on the membrane but also in the
Figure 2. Tyro 3 overexpression decreases the production of Ab from 293APPswe cells and Gas6 inhibits the effect in
a concentration-dependent manner. (A, B) ELISA assay shows that the levels of (A) Ab42 and (B) Ab40 are significantly reduced in Tyro 3-CFP
transfected cells relative to GFP transfected cells and the effect is inhibited by addition of Gas6 at the final concentration of 100 ng/ml. (C) The ratio
Ab42/Ab40 is also significantly lower in Tyro 3-CFP transfected cells than in GFP transfected cells. (D) ELISA assay shows that a decrease in Ab in Tyro-
3-transfected 293APPswe cells relative to the GFP transfected controls. Both sets of cells were treated with different concentrations of Gas6 (12.5, 25,
50, 100 ng/ml). Total Ab was also significantly lower in Tyro-3-transfected cells treated with low concentrations of Gas6 (12.5, 25 ng/ml) than in GFP
controls. ***P,0.001, **P,0.01 versus GFP controls (student’s t-test or one way ANOVA). Doses of 50 ng/ml or 100 mg/ml caused no obvious
changes in the Gas6-treated group.
doi:10.1371/journal.pone.0039035.g002
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normal functions as a receptor tyrosine kinase [13,14,18,19]. We
also found that Tyro3 overexpression alleviated Ab generation in
293APPswe cells. It has been discovered that the natural ligands of
Tyro3 receptor are protein S and Gas6. Gas6 is expressed in the
brain and has been shown to posses neuroprotective and
Figure 3. BACE1 protein level and activity are down-regulated by Tyro3 overexpression in 293APPswe cells. (A, B) Western blot
analysis of BACE1 showing that the protein levels of BACE1 in extracts from Tyro3-CFP transfected cells have lower fluorescent intensity than GFP
controls. (C, D, E) Increase in C99 (bCTF) protein level and decrease in C83 (aCTF) protein level in extracts from Tyro3-CFP transfected cells were
detected by western blot analysis compared to that of GFP control. *P,0.05, **P,0.01 versus GFP control (student’s t-test).
doi:10.1371/journal.pone.0039035.g003
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Gas6 to stimulate Tyro3 receptors to determine whether their
effect on APP processing and Ab production is dependent on their
ligand, Gas6. In striking contrast with our expectance, the effect of
Tyro3 overexpression on Ab production in 293APPswe cells was
found to be inhibited by the presence of Gas6 in a concentration-
dependent manner. Taking into account the presence of serum in
the culture medium of the 293APPswe cells, some factors,
especially Protein S, which is the other natural ligand of Tyro3
receptors, might stimulate Tyro3 receptor tyrosine kinase [25].
The other possibility is that Tyro3 itself might interact with APP or
some other factor related to APP processing. This requires
additional analysis.
We next explored how Tyro3 overexpression reduced Ab
generation in HEK293 cells through APPswe mutant proteins.
Increases in Ab production did not seem likely to be induced by
up-regulation of APPswe mutant protein expression because we
did not observe any changes in APP transgene expression when
Tyro3 was overexpressed in 293APPswe cells (data not shown).
The amyloidogenic APP processing complex, BACE1, is a pre-
dominant b-secretase enzyme responsible for Ab generation in the
brain [39,44]. Recent studies have shown that Ab generation,
amyloid pathology, electrophysiological dysfunction, and cognitive
deficits become abrogated when BACE1
2/2 mice are bred with
APP transgenic mice [45,46]. We also examined the expression of
BACE1 in 293APPswe cells and demonstrated that Tyro3
overexpression could decrease BACE1 protein levels in those
cells. This indicates that the decreased BACE1 levels are involved
in the mechanism by which Tyro3 receptors affect amyloidogenic
APP processing and Ab generation, as mentioned above. Gas6
treatment also inhibited the effects of Tyro3 receptor on BACE1
expression. Our results suggest that Tyro3 receptor contributes to
the inhibition of Ab production in transgenic cell models,
promoting the familial disease mutations in APP by suppressing
BACE1 protein expression. One counterintuitive part of our
results is that Gas6 impedes the ability of Tyro3 to inhibit Ab
production, which contradicts previous reports of the neuropro-
tective and neurotrophic effects of Gas6 on Alzheimer’s disease-
like disorders [13,14,21,23,26–28,37]. Analyzing those reports and
our observations, we speculate that the effects of Tyro3 on APP
processing are independent of Gas6-mediated signaling. The
manner by which Tyro3 receptors influence APP processing and
Ab accumulation in the progression of Alzheimer’s disease
requires further study. Fortunately, the progression of AD has
been studied in many kinds of Alzheimer’s transgenic mice. We
used APP/PS1 doubly transgenic mice co-expressing human PS1
and APP transgenes with a total of five FAD mutations including
the Swedish mutation in 293APPswe cells [40]. These transgenic
mice are characterized by rapid amyloid deposition, which
increases with age and reaches massive levels when the mouse is
6 months old. Interestingly, young 5XFAD mice produced Ab42
almost exclusively as early as 1.5 months of age, while the Ab40
Figure 4. Gas6 inhibits the decrease in BACE1 protein level induced by Tyro3 overexpression in 293APPswe cells. (A, B) Western blot
statistical analysis showed that BACE1 levels were significantly lower in Tyro 3-CFP transfected cells than in GFP controls. Gas6 treatment was found
to reverse this effect. *P,0.05 versus GFP control (two way ANOVA).
doi:10.1371/journal.pone.0039035.g004
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39035Figure 5. Tyro3 knockdown significantly increases Ab plaque formation in the CA1 and subiculum area but not in the DG region in
5XFAD mouse brains. A–L), Ab immunoreactive plaques in the (A–F) hippocampus (G–L) and cortex of (A–C, G–I) 5XFAD transgenic mice and (D–F,
J–K) 5XFAD; T2/+ crossed mice, respectively. 6E10 immunoreactive plaques are shown as red fluorescence and nuclei are stained blue by Hoechst.
CA1 and DG regions are indicated with lines. Scale bar=200 mm. (M–O) Enlarged plaques were detected by confocal laser scanning microscopy. Scale
bar=25 mm. (P, Q) Ab immunohistochemical images showing Ab-positive plaques in the subiculum of 5XFAD and 5XFAD; T2/+ mice. Scale
bar=500 mm. (R, S) Quantification of plaques showing both the number of plaques (Figure 5R-a, S-a) and average area occupied by plaques
(Figure 5R-b, S-b) are increased in CA1 and subiculum areas in 5XFAD; T2/+ mice compared with 5XFAD controls. However, the number of plaques in
DG region in 5XFAD; T2/+ mouse brain was much higher than that of 5XFAD controls. ***P,0.001, **P,0.01, *P,0.05 versus 5XFAD transgenic
controls (student’s t-test or two way ANOVA).
doi:10.1371/journal.pone.0039035.g005
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levels [40]. This phenomenon can be used to evaluate the role of
Tyro3 in Ab production and accumulation in the development of
AD in the brain.
Our studies show that partial knockdown of the Tyro3 receptor
promotes Ab deposition in AD transgenic brains, especially in
CA1 region of the hippocampus. The CA1 area is the exact brain
region that expresses Tyro3 receptor [23]. It supports long-term
potentiation (LTP), an electrophysiological measure related to
learning and memory [47,48]. It is the most important brain
region that is impaired in the progression of AD. Normal levels of
Tyro3 expression might play a beneficial role against Ab
production, deposition, and toxicity. The present knockdown
experiment also suggests the involvement of Tyro3 receptor in
reducing amyloid plaques in progression of AD. On the other
hand, the present study also provides a clue suggesting that the
pathological features of AD are closely associated with hippocam-
pal development: Tyro3 expression in CA1 pyramidal neurons is
first detected in 14.5 day old mouse embryos, which is when
hippocampal development begins [14,23]. Notably, the number of
amyloid plaques in the subiculum was noticeably higher in
5XFAD; Tyro3
2/+ transgenic brains than in 5XFAD mice brains.
The subiculum is also an important part of hippocampal
formation, that it is involved in learning and memory, and that
it is among the first parts of the brain to be damaged during AD
[40,48]. Taking this into account, our results suggest that Tyro3 is
closely related to hippocampal functions, such as LTP, and so is
associated with the pathogenesis of AD and might act as
a downstream molecule of amyloidogenic APP processing and
the amyloid cascade in the progression of AD, but this could be
a factor in turn blocking that process. Although the number of
amyloid plaques did not change in cortex – they even decreased
slightly in the dentate gyrus – we still found more and smaller
Figure 6. Tyro3 knockdown increases plaque-associated clusters of astroglia in 5XFAD mouse brains. (A, D) GFAP immunoreactive
astrocytes (brown) and plaques stained with Congo red dye (dense pink core) in the cortexes of (A) 5XFAD transgenic mice and (D) 5XFAD; T2/+
crossed mice, respectively (Scale bar=200mm). (C, F) Enlarged images are chosen from a field, which are surrounded by black frames as shown in (B)
and (E), centered on a putative amyloid plaque. Scale bar=50 mm. (G) Area occupied by GFAP-ir cells per total area under observation is increased in
brain slices of 5XFAD; T2/+ mice compared with 5XFAD controls. (H) Quantification analysis showing the average optical density (OD) of GFAP-ir
occupied area in 5XFAD; T2/+ mice is significantly higher than that of 5XFAD controls. ***P,0.001, **P,0.01 versus 5XFAD transgenic controls
(student’s t-test).
doi:10.1371/journal.pone.0039035.g006
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5XFAD; Tyro3
2/+ brains than in those of 5XFAD mice.
Although we have not quantified Ab levels in vivo, we speculate
that increasing levels of Ab, especially Ab42, in the brains of
5XFAD; Tyro3
2/+ transgenic mice may be responsible for the
increased number of amyloid plaques. This is indicated by the fact
that the amyloid plaques found in 5XFAD; Tyro3
2/+ transgenic
mice were typically smaller but had more concentrated cores than
those found in 5XFAD transgenic mice. The pronounced
astrogliosis surrounding the congophilic plaques supports this
conclusion because the amyloid pools caused by Ab accumulation
are more attractive to astrocytes [49,50]. Evidences showed that
Gas6 stimulated phagocytic response and regulated activation of
microglia, suggesting its receptors playing a role in mediating an
anti-inflammatory effect with the simultaneous stimulation of
phagocytosis [51]. Here, we performed microglia immunostaining
using anti-Iba1 antidody to detect microglial reactivity in 5XFAD
brain and 5XFAD; Tyro3
2/+ mouse brain. As the result, no
significant difference was seen in microglial immunoreactivity
between 5XFAD brain and 5XFAD; Tyro3
2/+ mouse brain. The
data indicated that the effect of Tyro3 on Ab accumulation might
be independent of Gas6-regulated inflammatory response. It has
been shown that the effect of Gas6 on phagocytosis and
inflammatory response is associated with activation of Mer and
Axl which are the other receptors for Gas6 [52,53]. In summary,
the present data may help researchers discover the role of the
Tyro3 in AD neuropathology. However, the exact mechanisms
underlying the influence of Tyro3 on APP processing and Ab
generation require further study.
Materials and Methods
Ethics Statement
The experimental procedures were carried out in accordance
with the Chinese regulations involving animal protection and
approved by the animal ethics committee of the China Capital
Medical University.
Cell culture, treatment, and transfection experiments
Human embryonic kidney 293 (HEK293) cell line was
purchased from ATCC (Manassas, VA) and the cells stably
transfected with human APP695 containing the Swedish APP670/
671 mutation (APPswe) expression plasmid (generously provided
by Dr. Yizheng Wang) were made using Lipofectamine 2000
Figure 7. Tyro3 knockdown has no effect on microglial activation in 5XFAD mouse brains. (A, B, C) Iba1 immunostaining in 5XFAD mouse
brain slices (Scale bar=200, 100, 50 mm, respectively). (D, E, F) Iba1 immunoreactive microglia in 5XFAD; T2/+ mouse brain slices (Scale bar=200,
100, 50 mm, respectively). (G) Quantification of mean optical density (OD) of Iba1 staining showing no significant difference between 5XFAD controls
and 5XFAD; T2/+ mouse brains. (H) Statistical analysis of ratio of area occupied by Iba1-ir cells to total area of image showing no significant change
between 5XFAD controls and 5XFAD; T2/+ mouse brains (student’s t-test).
doi:10.1371/journal.pone.0039035.g007
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using G418 (Merck) resistance. The cells were maintained in
Dulbecco’s minimum essential medium (Gibco) supplemented
with 10% heat-inactivated fetal bovine serum (HyClone) at 37uC
in a humidified incubator containing 5% CO2 and G418 at a final
concentration of 200 mg/ml. For overexpression experiments,
HEK293 cells stably expressing APPswe mutant (are called
293APPswe cells) were transiently transfected with full-length
Tyro3-eCFP fusion or eGFP expression plasmids using Lipofecta-
mine 2000 reagent. For Gas6 treatment, cells were treated with
Gas6 at different final concentration for 24 h for transfection of
Tyro3-eCFP or eGFP. The supernatants were collected and
subjected to ELISA assay, and the cells were harvested for
Western blot analysis.
Plasmids: pCMV-Tyro3-eCFP construct was generated by
insertion of PCR amplified mouse Tyro3 coding region into
pCMV-eCFP. pCMV-eGFP expression plasmid was used as
control. All these plasmids were generously provided by Dr.
Qingxian Lu.
Western blotting
Culture cell lysates were prepared from experimental cells with
the Cellytic buffer containing protease inhibitor cocktail (1:100,
SigmaAldrich) for 30 min at room temperature followed by
sonication on ice for 1 min. They were then centrifuged at
12,000 r.p.m. for 30 min at 4uC. The supernatants were collected
and total protein levels were measured using a UV 1700
PharmaSpec ultraviolet spectrophotometer by Bradford method
according to the manufacturer’s procedure (Bio-Rad). Proteins
(50 mg) were analyzed on 10% SDS-PAGE gels, and electropho-
retically transferred to nitrocellulose membranes (Milipore).
Western blot membranes were blocked with 5% nonfat dry milk
in 16PBS for 2 h at room temperature, and further incubated
overnight at 4uC with corresponding primary antibodies. Anti-
bodies used for Western blot analysis include mouse anti-APP695
(1:1000, 13-0200; ZYMED Laboratories), rabbit anti-Tyro3
(1:500, sc20742; Santa Cruz), rabbit anti-BACE1 (1:1000, PA1-
757; Thermo), and mouse anti-GAPDH (1:20000, G8795;
SigmaAldrich). The primary antibody labeled membranes were
then treated with IRDye
TM 800 (green) or IRDye
TM 700 (red)
conjugated affinity purified anti-rabbit or anti-mouse IgG (Rock-
land) for 1 h. They were then washed three times with PBS
containing 0.1% Tween and twice with PBS alone. The positive
Western bands were visualized by LI-COR Odyssey infrared
double-fluorescence imaging system (American Company LI-
COR).
Sandwich ELISA
The supernatant of cell cultures were collected and placed on
ice and protease inhibitor cocktail was added at a 1:100 dilution
and then centrifuged at 12,000 r.p.m. for 30 min at 4uC. The
supernatants were loaded on to 96-well plates and soluble Ab was
detected using a total human Ab ELISA kit (EH025–48; Excell),
human Ab42 ELISA kit (KHB3441; Invitrogen) or human Ab40
ELISA kit (KHB3481; Invitrogen) in accordance with the
manufacturer’s instructions. The absorbance was read at
450 nm using a 96 well plate reader.
Immunohistochemistry with fluorescent and confocal
laser scanning microscopy
To render the transfection assay more efficient, live 293APPswe
cells transfected with Tyro3-CFP expression plasmid spreading
poly-L-lysine-coated coverslips for 24 h were placed on slides with
a drop of 75% glycerol in PBS and subjected to observation with
confocal laser scanning microscopy (Leica). Six-month-old female
mice were deeply anaesthetized with sodium pentobarbital
(50 mg/kg, i.p.) and then perfused transcardially with 0.9%
sodium solution, followed by paraformaldehyde in 0.1 M PBS.
Their brains were immediately removed and transferred to fresh
4% paraformaldehyde overnight at 4uC. The brains were then
cryoprotected by infiltration in 30% sucrose in 0.1 M PBS at 4uC
until they sank to the bottoms of 50 ml centrifuge tubes. The
brains were embedded in OCT compound. Then cryostat sections
were cut and allowed to air dry on SuperPlus glass slides. Serial
10 mm coronal sections were prepared and the standard ABC
method was used to determine the distribution of amyloid plaques
in 56FAD and 56FAD; Tyro3
2/+ mice brains. The cryostat
sections were washed with 0.1 M PBS and treated in 0.1 M PBS
buffer containing 3% hydrogen peroxide (H2O2) for 20 min
followed by incubation in normal goat serum (1:20) for 30 min.
Then the sections were incubated overnight with mouse anti-Ab
6E10 (1:1000, SIG-39300; Covance) or mouse anti-GFAP (1:500,
MAB360; Millipore) or rabbit anti-Iba1(1:200, wako, Japan) at
4uC in a humidified chamber. After rinsing in the next day,
sections were incubated with biotinylated goat anti-mouse IgG
(1:200) for 2 h at room temperature, followed by amplification
with streptavidin peroxidase for 1 h. The sections were rinsed and
then treated with diaminobenzidine (DAB) diluted in chromogenic
substrate for 5 min until positive brown DAB images showed up.
For congophilic staining, the immunostained sections mentioned
above were incubated in 0.2% Congo red for 5 min and
differentiated using alkaline alcoholic solution. They were then
rinsed 3 times. The stained sections were dehydrated, cleared, and
covered with neutral balsam. Sections were examined and images
were collected using a light microscope equipped with a digital
camera (Olympus).
For fluorescence immunohistochemistry, sections were permea-
bilized with 0.2% TritonX-100 in PBS, pH 7.4 for 20 min at
room temperature, blocked in PBS buffer containing 5% normal
goat serum for 30 min and incubated in the primary antibodies
overnight in a humidified chamber at 4uC. After washing with
16PBS for 3 times for 5 min each. The sections were incubated
for 30 min at 4uC and then 30 min at 37uC with Rhodamine
(TRITC)-conjugated goat anti-mouse IgG. After washing, the
sections were sealed with coverslips with fluorescent protection
mounting media (Vector Laboratories). These sections were
observed with fluorescent or laser scanning confocal microscopy
(Leica).
The number of Ab-positive plaques in the cortex and
hippocampus formation was calculated using Image Pro Plus 6.0
software. Briefly, 20 consecutive sections of each mouse cortex and
hippocampus were imaged together and the areas and the total
counts of Ab-positive plaques in sections per six mouse brains of
each group were determined using the software. The level of
GFAP or Iba1 immunoreactivity was measured by using mean
optical density of DAB staining. In addition, ratio of area of object
to total area of image was also obtained by the software. The white
balance of all images was standardized to eliminate color bias.
Animals
We used APP/PS1 doubly transgenic mice co-expressing and
co-inheriting both human APP and PS1 transgenes with a total of
five FAD mutations under transcriptional control of the neuron-
specific mouse Thy-1 promoter (5XFAD mice, Tg6799 line) [40].
The 5XFAD mice carry an APP transgene with triple FAD
mutations (Swedish mutation: K670N, M671L, Florida mutation:
I716V; London mutation: V717I) and a PS1 transgene carrying
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were originally purchased from Jackson Laboratory and main-
tained by crossing heterozygous transgenic mice with C57BL/6J
wild type breeders. Genotyping was performed by PCR analysis of
tail DNA. Hemizygous 5XFAD mice were crossbred with
Tyro3
2/2 mice and the resultant F1 progeny, including 5XFAD;
Tyro3
2/+ were obtained. The simultaneously obtained offspring of
5XFAD transgenic mice crossed with their littermates were used as
controls. Tyro3
2/2 mice (provided by Dr. Qingxian Lu) with
SlKSw/129 background had been backcrossed with C57BL/6J
mice for at least 20 generations. All these mice were kept in cages
in a controlled environment (22–25uC, 50% humidity, 12 h light/
dark cycle). The mice were fed a standard diet and distilled water
was available ad libitum.
Data analysis
All experiments were performed in at least three independent
assays. Data are summarized as means 6 standard errors.
Statistical analysis of the results was performed by Student’s t
testing for unpaired samples or two-way ANOVA model using
Prism4.0 software (GraphPad Software, San Diego, CA, U.S.). P
values of ,0.05 were considered statistically significant.
Supporting Information
Figure S1 Establishment of HEK293 cells stably overexpressing
APPswe mutants. (A) Western blot for APP of protein extracts of
wild-type HEK293 cells (293WT) and HEK293 cells overexpres-
sing APPswe mutants (293APPswe). GAPDH was used as a loading
control. The level of APP expressed in 293APPswe cells is
increased. (B) Relative fluorescent intensity of Western blots shows
a significant increase in the levels of APP in 293APPswe cells.
Statistical analysis was performed using the student’s t-test
(**P,0.01).
(TIF)
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